Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 1 Apr 2023

Wang Shuai, Wu Jingheng, Zhao Wujun, Li Miaomiao, Li Shaoyi

Abstract excerpt

Temozolomide (TMZ), the primary drug for glioma treatment, has limited treatment efficacy. Additionally, considerable evidence shows that isocitrate dehydrogenase 1 mutation-type (IDH1 mut) gliomas have a better response to TMZ than isocitrate dehydrogenase 1 wildtype (IDH1 wt) gliomas. Here, we aimed to identify potential mechanisms underlying this phenotype. Herein, the Cancer Genome Atlas bioinformatic data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Isocitrate Dehydrogenase
Share to CCAAT-Enhancer-Binding Protein-beta

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Cell Proliferation

Share to Glioma

Share to Mutation

Share to Temozolomide

Source

Identifiers

PMID: 36906285
DOI: 10.1096/fj.202201244RRRR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma.PMID 36906285Read ↗

P4HA2 is associated with prognosis, promotes proliferation, invasion, migration and EMT in gliomaSemantic proximity Read ↗

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.Semantic proximity Read ↗

COL4A1 as a novel oncogene associated with the clinical characteristics of malignancy predicts poor prognosis in gliomaSemantic proximity Read ↗

Unraveling the tumor-promoting role of wildtype Isocitrate dehydrogenase 1 (IDH1) in human gliomasSemantic proximity Read ↗

PSMC2/E2F1 Axis Promotes the Development and Progression of GliomaSemantic proximity Read ↗

Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in <i>IDH1</i> -mutant gliomaSemantic proximity Read ↗

The effects of BMP2 and the mechanisms involved in the invasion and angiogenesis of IDH1 mutant glioma cells.Semantic proximity Read ↗

High expression of HOXA4 in patients with glioma indicates unfavorable clinical outcomes.Semantic proximity Read ↗

Elucidating the Predominant Role of AEBP1 in Different Types of Cancers with a Focus on Glioblastoma Progression – A ReviewSemantic proximity Read ↗

IDH1 overexpression induced chemotherapy resistance and IDH1 mutation enhanced chemotherapy sensitivity in Glioma cells in vitro and in vivo.Semantic proximity Read ↗

Integrated genomic characterization of IDH1-mutant glioma malignant progression.Semantic proximity Read ↗

TMEM2 Combined with IDH and 1p19q in Refining Molecular Subtypes for Predicting Survival of Patients with Glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.